Navigation Links
BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

erformance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further deve
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
2. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
3. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
4. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
5. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
6. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
7. Prescription Drugs: Good Medicine - Bad Behavior; Science Matters Program Explores the Rise in Prescription Drug Abuse Presented by the California Science Center
8. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
9. eResearchTechnology, Inc. to Present at the UBS Global Healthcare Services Conference on February 10, 2009
10. Triple-S Management Corporation to Present at UBS Global Healthcare Services Conference
11. International Medical Interpreter Association Appoints IMIA State Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter , ... been believed to improve overall health, but a growing body ... heart, a new review finds. In fact, the benefits ... walking, said lead researcher Paula Chu, a doctoral candidate at ... of 37 clinical trials, found that people randomly assigned to ...
(Date:12/15/2014)... CARSON CITY, NV (PRWEB) December 15, 2014 ... new powerhouse company, JM Ocean Avenue. JM Ocean ... technology of the Veretekk online automated marketing system. ... by the June 2014 merger of Ocean Avenue and ... a more than $2 Billion per year company. , ...
(Date:12/15/2014)... MD (PRWEB) December 15, 2014 ... services today released “ Social Media Cheat Sheets ,” ... a community that drives results on the top ten ... marketing program. It helps drive awareness, engagement, and customer ... For marketers to make an impact on new networks ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in ... is contributing to the growth in the global audiological market. ... hearing loss and balance disorders are known as audiological devices. ... and amplifier. The global market is expected to grow at ... from 2014 to 2019. Some of the factors which are ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... with a history of severe milk allergy can safely drink ... research led by the Johns Hopkins Children,s Center and published ... of Allergy and Clinical Immunology . Investigators followed up ... earlier Hopkins Children,s-led study published in 2008 in which patients ...
... , NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: ... that identifies, acquires, and develops novel drug targets that ... Whiteman as its Chief Executive Officer. , Mr. Whiteman, ... London School of Economics . He will provide ...
... , Miami ... Area , , ... today to participating in a conspiracy to defraud the Medicare program of ... Division, U.S. Attorney Terrence Berg of the Eastern District of Michigan and ...
... , HATBORO, Pa., Aug. 18 ... IFLG ), a leading technology provider of enterprise ... that it has successfully achieved Motorola,s Enterprise Mobility Validation for ... Controller (MDC), InfoLogix,s innovative application platform for mobile ...
... , MOUNT PROSPECT, Ill., Aug. 18 The ... KnujOn for spotlighting the exploitation of search engines, advertising programs ... Prescription Drug Sponsored Search Results," released on August 18, 2009, ... Yahoo!,s online advertising program. , , ...
... , PRINCETON, N.J., Aug. 18 Covance (NYSE: ... with Merck to provide a broad array of genomics analysis services ... Gene Expression Laboratory. Effective August 17, 2009, Covance assumed control ... , About Covance , Covance, with ...
Cached Medicine News:Health News:Milk is safe, even encouraged, for some children after treatment for milk allergy 2Health News:GENova names Aaron Whiteman as CEO 2Health News:GENova names Aaron Whiteman as CEO 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 2Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 4Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 2Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 3Health News:NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets 2Health News:Covance and Merck & Co., Inc. Finalize Strategic Agreement 2
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... N.J. , Dec. 15, 2014   Regeneron ... and NYSE: SNY) are collaborating with nationally-recognized patient and ... , an awareness program that will gauge how much ... associated with high LDL-C (bad cholesterol).  American adults are ... take a brief poll and answer a few key ...
(Date:12/15/2014)... , Dec. 15, 2014   DaVita HealthCare ... of the nation,s largest and most innovative health ... business units, DaVita Clinical Research  (DCR) and  HealthCare ... further expand its extensive clinical research and data ... disease (CKD) and end-stage renal disease (ESRD), as ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Sept. 22, 2011 Pain can affect anyone regardless ... have difficulty getting adequate pain care. Women, certain ethnic ... to be denied appropriate pain treatment.(1),(2) In the ... Purdue Pharma L.P. for pain management advocacy, offers new ...
... Sept. 22, 2011 Leaders from government, industry, academia, ... one of the most pressing health challenges we face: ... of new antibiotics to fight them.  The conference, "Reviving ... Innovation," is organized by the Pew Health Group, the ...
Cached Medicine Technology:In The Face of Pain® Offers New Tools and Resources to Patients, Caregivers and Healthcare Professionals Advocating for Better Pain Care 2In The Face of Pain® Offers New Tools and Resources to Patients, Caregivers and Healthcare Professionals Advocating for Better Pain Care 3Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs 2Antibiotics Conference Addresses Lack of New Drugs to Fight Deadly Superbugs 3
... Forms strong flexible gels for ... clarifier: mixture of wide range ... water 10 mg/mL, clear, faintly ... molecular biology MP: 90 °C ...
Inquire...
Inquire...
... Melt), A low temperature agarose for ... , Optimal for in-gel restriction digestion/ligation and ... very manageable clear gel that provides excellent ... approximately 65°C and remains fluid at 37°C ...
Medicine Products: